دورية أكاديمية
Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment
| العنوان: | Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment |
|---|---|
| المؤلفون: | Abubakr O. A. Adam, Mohamed M. M. Dafalla, Hatim A. A. Mohammed, Mohamed Y. Elamin, Brima M. Younis, Mona E. E. Elfaki, Ahmed M. Musa, Ahmed M. Elhassan, Eltahir A. G. Khalil |
| المصدر: | Annals of Saudi Medicine, Vol 34, Iss 2, Pp 143-146 (2014) |
| بيانات النشر: | King Faisal Specialist Hospital and Research Centre, 2014. |
| سنة النشر: | 2014 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | Medicine |
| الوصف: | BACKGROUND AND OBJECTIVES: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In Sudan, VL is caused by L donovani. Most drugs used to treat VL, especially pentavalent antimony compounds (sodium stibogluconate, SSG), are potentially hepatotoxic. A number of fatal catastrophes happened because patients with VL-hepatitis B/C coinfection were indiscriminately treated with SSG in settings where VL and viral hepatitis coexist. This study aimed to study biochemical and hematological parameters of patients with VL-hepatitis B/C coinfections with the aim to modify treatment protocols to reduce coinfection-added morbidity and mortality. DESIGN AND SETTINGS: This was a prospective analytical, hospital-based, and case-controlled study. The study was done at Kassab Hospital and Professor Elhassan Centre for tropical medicine during the period of February 2008 to April 2013. MATERIALS AND METHODS: Following informed consent by the participants, 78 parasitologically confirmed VL patients with either hepatitis B or C or both and 528 sex- and age-unmatched VL patients without hepatitis B/C coinfection (control group) were enrolled sequentially. Diagnosis of hepatitis B or C was made using immunochromatographic test kits and confirmed by an enzyme-linked immunosorbent assay. RESULTS: VL patients with hepatitis B/C coinfections had significantly increased levels of AST, ALT, and total bilirubin compared to the control group (P=.0001 for all), with significantly decreased levels of albumin and platelets counts (P=.0029 for both). CONCLUSION: VL-hepatitis B/C coinfections are an emerging entity that needs anti-leishmanial treatment modification. Alternative treatments like paromomycin and amphotericin B (AmBisome) could be reserved for these patients. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0256-4947 0975-4466 |
| العلاقة: | https://doaj.org/toc/0256-4947Test; https://doaj.org/toc/0975-4466Test |
| DOI: | 10.5144/0256-4947.2014.143 |
| الوصول الحر: | https://doaj.org/article/2d9f66f032c64911b67b98aa86727689Test |
| رقم الانضمام: | edsdoj.2d9f66f032c64911b67b98aa86727689 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 02564947 09754466 |
|---|---|
| DOI: | 10.5144/0256-4947.2014.143 |